FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023447635> ?p ?o ?g. }

• W2023447635 endingPage "2070" @default.
• W2023447635 startingPage "2061" @default.
• W2023447635 abstract "Objective: To determine the feasibility and potential usefulness of mathematical models in evaluating immunomodulatory strategies in clinical trials of severe sepsis. Design: Mathematical modeling of immunomodulation in simulated patients. Setting: Computer laboratory. Measurements and Main Results: We introduce and evaluate the concept of conducting a randomized clinical trial in silico based on simulated patients generated from a mechanistic mathematical model of bacterial infection, the acute inflammatory response, global tissue dysfunction, and a therapeutic intervention. Trial populations are constructed to reflect heterogeneity in bacterial load and virulence as well as propensity to mount and modulate an inflammatory response. We constructed a cohort of 1,000 trial patients submitted to therapy with one of three different doses of a neutralizing antibody directed against tumor necrosis factor (anti-TNF) for 6, 24, or 48 hrs. We present cytokine profiles over time and expected outcome for each cohort. We identify subgroups with high propensity for being helped or harmed by the proposed intervention and identify early serum markers for each of those subgroups. The mathematical simulation confirms the inability of simple markers to predict outcome of sepsis. The simulation clearly separates cases with favorable and unfavorable outcome on the basis of global tissue dysfunction. Control survival was 62.9% at 1 wk. Depending on dose and duration of treatment, survival ranged from 57.1% to 80.8%. Higher doses of anti-TNF, although effective, also result in considerable harm to patients. A statistical analysis based on a simulated cohort identified markers of favorable or adverse response to anti-TNF treatment. Conclusions: A mathematical simulation of anti-TNF therapy identified clear windows of opportunity for this intervention as well as populations that can be harmed by anti-TNF therapy. The construction of an in silico clinical trial could provide profound insight into the design of clinical trials of immunomodulatory therapies, ranging from optimal patient selection to individualized dosage and duration of proposed therapeutic interventions." @default.
• W2023447635 created "2016-06-24" @default.
• W2023447635 creator A5034374861 @default.
• W2023447635 creator A5039419259 @default.
• W2023447635 creator A5053511755 @default.
• W2023447635 creator A5073022985 @default.
• W2023447635 creator A5078253661 @default.
• W2023447635 creator A5082272833 @default.
• W2023447635 date "2004-10-01" @default.
• W2023447635 modified "2023-10-16" @default.
• W2023447635 title "In silico design of clinical trials: A method coming of age" @default.
• W2023447635 cites W12631836 @default.
• W2023447635 cites W1660272337 @default.
• W2023447635 cites W1965860115 @default.
• W2023447635 cites W1971537896 @default.
• W2023447635 cites W1971775137 @default.
• W2023447635 cites W1985264236 @default.
• W2023447635 cites W1988390189 @default.
• W2023447635 cites W1992033406 @default.
• W2023447635 cites W1992859813 @default.
• W2023447635 cites W1999897608 @default.
• W2023447635 cites W2000083184 @default.
• W2023447635 cites W2003564462 @default.
• W2023447635 cites W2010982832 @default.
• W2023447635 cites W2019043807 @default.
• W2023447635 cites W2028553295 @default.
• W2023447635 cites W2030879735 @default.
• W2023447635 cites W2038697192 @default.
• W2023447635 cites W2040068581 @default.
• W2023447635 cites W2044125495 @default.
• W2023447635 cites W2046692671 @default.
• W2023447635 cites W2053033670 @default.
• W2023447635 cites W2057597640 @default.
• W2023447635 cites W2059908643 @default.
• W2023447635 cites W2076642686 @default.
• W2023447635 cites W2080354420 @default.
• W2023447635 cites W2081371688 @default.
• W2023447635 cites W2086949509 @default.
• W2023447635 cites W2087203965 @default.
• W2023447635 cites W2092762545 @default.
• W2023447635 cites W2115301416 @default.
• W2023447635 cites W2117446946 @default.
• W2023447635 cites W2120356605 @default.
• W2023447635 cites W2122138110 @default.
• W2023447635 cites W2123566103 @default.
• W2023447635 cites W2124925985 @default.
• W2023447635 cites W2130610340 @default.
• W2023447635 cites W2141380939 @default.
• W2023447635 cites W2141685355 @default.
• W2023447635 cites W2142585662 @default.
• W2023447635 cites W2150704630 @default.
• W2023447635 cites W2152834577 @default.
• W2023447635 cites W2322121630 @default.
• W2023447635 cites W2550507245 @default.
• W2023447635 cites W30597232 @default.
• W2023447635 cites W76818083 @default.
• W2023447635 doi "https://doi.org/10.1097/01.ccm.0000142394.28791.c3" @default.
• W2023447635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15483415" @default.
• W2023447635 hasPublicationYear "2004" @default.
• W2023447635 type Work @default.
• W2023447635 sameAs 2023447635 @default.
• W2023447635 citedByCount "178" @default.
• W2023447635 countsByYear W20234476352012 @default.
• W2023447635 countsByYear W20234476352013 @default.
• W2023447635 countsByYear W20234476352014 @default.
• W2023447635 countsByYear W20234476352015 @default.
• W2023447635 countsByYear W20234476352016 @default.
• W2023447635 countsByYear W20234476352017 @default.
• W2023447635 countsByYear W20234476352018 @default.
• W2023447635 countsByYear W20234476352019 @default.
• W2023447635 countsByYear W20234476352020 @default.
• W2023447635 countsByYear W20234476352021 @default.
• W2023447635 countsByYear W20234476352022 @default.
• W2023447635 countsByYear W20234476352023 @default.
• W2023447635 crossrefType "journal-article" @default.
• W2023447635 hasAuthorship W2023447635A5034374861 @default.
• W2023447635 hasAuthorship W2023447635A5039419259 @default.
• W2023447635 hasAuthorship W2023447635A5053511755 @default.
• W2023447635 hasAuthorship W2023447635A5073022985 @default.
• W2023447635 hasAuthorship W2023447635A5078253661 @default.
• W2023447635 hasAuthorship W2023447635A5082272833 @default.
• W2023447635 hasConcept C126322002 @default.
• W2023447635 hasConcept C143998085 @default.
• W2023447635 hasConcept C168563851 @default.
• W2023447635 hasConcept C177713679 @default.
• W2023447635 hasConcept C17991360 @default.
• W2023447635 hasConcept C201903717 @default.
• W2023447635 hasConcept C2778384902 @default.
• W2023447635 hasConcept C535046627 @default.
• W2023447635 hasConcept C71924100 @default.
• W2023447635 hasConcept C72563966 @default.
• W2023447635 hasConceptScore W2023447635C126322002 @default.
• W2023447635 hasConceptScore W2023447635C143998085 @default.
• W2023447635 hasConceptScore W2023447635C168563851 @default.
• W2023447635 hasConceptScore W2023447635C177713679 @default.
• W2023447635 hasConceptScore W2023447635C17991360 @default.
• W2023447635 hasConceptScore W2023447635C201903717 @default.
• W2023447635 hasConceptScore W2023447635C2778384902 @default.

• next